To pinpoint the impact of P‐cadherin in GBM, we firstly performed in vitro functional assays using an overexpression approach, in which CDH3/P‐cadherin was overexpressed in U87 cells (a commercially available GBM cell line with very low or undetectable levels of CDH3/P‐cadherin by qRT‐PCR and western blot). The gene discussed is CDH3; the disease is glioblastoma.